Please login to the form below

Not currently logged in
Email:
Password:

Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

The deal represents a major expansion for Sobi, which is currently focused on rare diseases and haemophilia in Europe (the latter through a licensing deal with Bioverativ), with limited penetration into

Latest news

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... only with its rare disease focus but also enhances its portfolio of products for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics